Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study

This phase II trial studies the effect of atezolizumab and cabozantinib in treating adolescents and young adults with osteosarcoma that has come back (recurrent) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab and cabozantinib may help to control the osteosarcoma.

Trial Details

NCT ID
NCT05019703
Phase
PHASE2
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • Atezolizumab
  • Cabozantinib
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Signed informed consent form
  • Age \>= 12 years at time of signing informed consent form
  • Ability to comply with the study protocol, in the investigator's judgment
  • Histologically confirmed diagnosis of osteosarcoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →